Epidarex Capital is a transatlantic life science venture capital firm based in Edinburgh and Bethesda. Since inception, the firm has focused on building companies around breakthrough academic science from leading UK and US research hubs. Epidarex backs founders and researchers working on high impact healthcare innovations with the potential to address major unmet medical needs across oncology, cardiometabolic disease, autoimmune conditions, and neurological disorders.
Epidarex Capital IV held a first close of more than 145 million dollars in January 2026. Initial LPs include the British Business Bank, Strathclyde Pension Fund, the Scottish National Investment Bank, as well as international corporates, family offices, and other institutional backers.
Fund IV will invest in up to 15 early stage companies developing transformative healthcare solutions based on foundational scientific discoveries. The vehicle is designed to bridge the equity funding gap for early stage therapeutics and health innovations, enabling breakthrough science to advance toward clinical milestones and commercial validation.
Epidarex plans to lead early financings, work closely with founders, and take an active role in building management teams and shaping strategy. The goal is to create globally competitive life science companies anchored in high quality research emerging from both sides of the Atlantic.
Leadership
The firm is led by managing partners Sinclair Dunlop and Elizabeth Roper, supported by a transatlantic investment team experienced in building healthcare companies from scientific inception through value inflection.
Investment Strategy
Epidarex focuses on company creation and early stage venture building. The firm works directly with researchers and entrepreneurs to spin out scientific breakthroughs, assemble leadership teams, and map clinical and regulatory pathways. It leads the earliest rounds, often serving as the first institutional investor. The strategy emphasizes disciplined capital deployment, scientific rigor, and hands on operational support to advance drug candidates and technologies toward meaningful clinical progress.
Notable Investments
The transatlantic portfolio includes:
Notable Exits
Not publicly disclosed.
Other
Epidarex has deep networks across UK and US academic medical centers, allowing founders early access to translational expertise, clinical collaborators, and commercial partners.
The firm is known for creating companies directly out of research labs and supporting them through their earliest and most challenging development stages.
United Kingdom
